Therapeutically, in efforts to target PERK-ATF4 axis in PD, oral administration of the small molecule GSK2606414 to mice models of PD has resulted in the inhibition of PERK activity in the SNpc after experimental ER stress stimulation with tunicamycin [157]. This evidence concerns the gene ATF4 and Parkinson disease.